OR WAIT null SECS
© 2021 MJH Life Sciences and Applied Clinical Trials Online. All rights reserved.
© 2021 MJH Life Sciences™ and Applied Clinical Trials Online. All rights reserved.
Jill Wechsler is ACT's Washington Editor
September 21, 2021
If the debate over vaccines for adults and the need for extra booster shots has been heated, FDA will face even more scrutiny over the safety and value of vaccinating children under age 12.
September 20, 2021
FDA’s Vaccines and Related Biological Products Advisory Committee announces its recommendations for the authorization of a third dose of the Pfizer/BioNTech Comirnaty vaccine.
September 17, 2021
Democrats failed to gain sufficient support this week to advance long-debated legislation to permit Medicare drug price negotiations.
September 14, 2021
FDA is launching a program to test the safety and suitability of novel inactive ingredients for use in new drugs and biologics.
September 10, 2021
White House officials recently announced a nearly $3 billion program to ramp up production of vaccines and their components to better serve patients in the U.S. and globally.
September 02, 2021
A report from the bipartisan Congressional Budget Office analyzes how drug pricing policies could reduce the number of new therapies coming to market.
August 30, 2021
FDA has revealed its plan for revising and renewing its fee program for drugs and biologics.
August 24, 2021
The first COVID-19 vaccine, Comirnaty, has received FDA approval. How will vaccination rates be effected?
August 20, 2021
While biopharma companies will pay more than $3 million to file an NDA or BLA application during fiscal year 2022, new fees for generic drugs will see modest or no increases and those for biosimilars may drop or hold even.
August 13, 2021
The White House is looking to pay for some of its prime social and health initiatives by reducing outlays for prescription drugs, according to an announcement by President Biden.